Correspondence 0001193125-23-291715 from MADRIGAL PHARMACEUTICALS, INC. (MDGL) (CIK 0001157601) (MDGL)
MADRIGAL PHARMACEUTICALS, INC. (MDGL) (CIK 0001157601)
Date: Dec. 8, 2023 · CIK: 0001157601 · Accession: 0001193125-23-291715
AI Filing Summary & Sentiment
File numbers found in text: 001-33277
Letter
VIA EDGAR Division of Corporate Finance Office of Life Sciences Washington, D.C. 20549 Re: Madrigal Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 File No. 001-33277
Dear Messrs. Newberry and Kuhar:
Madrigal Pharmaceuticals, Inc. (the “Company”) received a comment letter from the U.S Securities and Exchange Commission (the “SEC”) dated November 21, 2023 in regard to the above referenced filing. The Company contacted the SEC staff to request an extension of time to respond beyond the period indicated in the letter and was granted an extension to respond no later than December 14, 2023.
Please direct any comments or questions to me at 267-824-2827.
Sincerely,
Madrigal Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP December 8, 2023 VIA EDGAR Mr. Gary Newberry Mr. Kevin Kuhar Division of Corporate Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Madrigal Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 File No. 001-33277 Dear Messrs. Newberry and Kuhar: Madrigal Pharmaceuticals, Inc. (the “Company”) received a comment letter from the U.S Securities and Exchange Commission (the “SEC”) dated November 21, 2023 in regard to the above referenced filing. The Company contacted the SEC staff to request an extension of time to respond beyond the period indicated in the letter and was granted an extension to respond no later than December 14, 2023. Please direct any comments or questions to me at 267-824-2827. Sincerely, Madrigal Pharmaceuticals, Inc. /s/ Brian J. Lynch Brian J. Lynch Senior Vice President and General Counsel